Pierre Jean Guillausseau

Summary

Country: France

Publications

  1. ncbi request reprint [Compliance and optimisation of oral antidiabetic therapy. A longitudinal study]
    Pierre Jean Guillausseau
    Service de Medecine B, Hopital Lariboisiere, 2 rue Ambroise Pare, 75010 Paris Université Paris 7
    Presse Med 33:156-60. 2004
  2. ncbi request reprint Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administration
    Pierre Jean Guillausseau
    Department of Medicine B, Lariboisiere Hospital, University Paris 7 Denis Diderot, Paris, France
    Treat Endocrinol 4:167-75. 2005
  3. ncbi request reprint Maternally inherited diabetes and deafness: a multicenter study
    P J Guillausseau
    Department of Medicine B, Lariboisiere Hospital, 2 rue Ambroise Pare, F75010 Paris, University Paris 7 Denis Diderot, France
    Ann Intern Med 134:721-8. 2001
  4. ncbi request reprint [Compliance to treatment and type 2 diabetes: impact on glycemic balance]
    Pierre Jean Guillausseau
    Presse Med 32:70. 2003
  5. ncbi request reprint [Urinary tract infections and diabetes mellitus]
    Pierre Jean Guillausseau
    Service de Medecine B, Hopital Lariboisiere, 75475 Paris
    Rev Prat 53:1790-6. 2003
  6. ncbi request reprint [Pathogenesis of type 2 diabetes mellitus]
    P J Guillausseau
    Service de médecine interne B, Hopital Lariboisiere, 2, rue Ambroise Pare, 75475 Paris 10, France
    Rev Med Interne 24:730-7. 2003
  7. ncbi request reprint [Type II diabetes in children and adults]
    Pierre Jean Guillausseau
    Service de Medecine B, hôpital Lariboisière et faculté de médecine Lariboisière Saint Louis, Universite Paris 7 Denis Diderot, 75475 Paris
    Rev Prat 53:1463-71. 2003
  8. ncbi request reprint Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice
    P J Guillausseau
    Service de Medecine B, Hopital Lariboisiere, Paris et Université Paris 7 Denis Diderot, France
    Diabetes Metab 29:79-81. 2003
  9. ncbi request reprint 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily
    P J Guillausseau
    Service de Medecine B, Hopital Lariboisiere, 2 rue Ambroise Pare, 75010 Paris, France
    Diabetes Metab 27:133-7. 2001
  10. ncbi request reprint Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance
    Franck Mauvais-Jarvis
    Department of Endocrinology and Diabetes, Saint Louis Hospital and University of Paris VII School of Medicine, Paris, France
    Diabetes 53:645-53. 2004

Detail Information

Publications18

  1. ncbi request reprint [Compliance and optimisation of oral antidiabetic therapy. A longitudinal study]
    Pierre Jean Guillausseau
    Service de Medecine B, Hopital Lariboisiere, 2 rue Ambroise Pare, 75010 Paris Université Paris 7
    Presse Med 33:156-60. 2004
    ..5 to 56.8%, and increase in percentage of once-daily dosing regimen from 12 to 58.4%...
  2. ncbi request reprint Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administration
    Pierre Jean Guillausseau
    Department of Medicine B, Lariboisiere Hospital, University Paris 7 Denis Diderot, Paris, France
    Treat Endocrinol 4:167-75. 2005
    ..Therefore, optimization of treatment through a reduction in the frequency of antihyperglycemic administration could be a valuable weapon in the battle to improve health outcomes and reduce the burden of type 2 diabetes...
  3. ncbi request reprint Maternally inherited diabetes and deafness: a multicenter study
    P J Guillausseau
    Department of Medicine B, Lariboisiere Hospital, 2 rue Ambroise Pare, F75010 Paris, University Paris 7 Denis Diderot, France
    Ann Intern Med 134:721-8. 2001
    ..Maternally inherited diabetes and deafness (MIDD), which is seen in 0.5% to 2.8% of patients with type 2 diabetes mellitus, is related to a point mutation at position 3243 of mitochondrial (mt) DNA. Its clinical description is incomplete...
  4. ncbi request reprint [Compliance to treatment and type 2 diabetes: impact on glycemic balance]
    Pierre Jean Guillausseau
    Presse Med 32:70. 2003
  5. ncbi request reprint [Urinary tract infections and diabetes mellitus]
    Pierre Jean Guillausseau
    Service de Medecine B, Hopital Lariboisiere, 75475 Paris
    Rev Prat 53:1790-6. 2003
    ..Nosocomial UTI is frequent in such patients. Meticulous preventive measures are the best means of reducing the prevalence of UTI in diabetics...
  6. ncbi request reprint [Pathogenesis of type 2 diabetes mellitus]
    P J Guillausseau
    Service de médecine interne B, Hopital Lariboisiere, 2, rue Ambroise Pare, 75475 Paris 10, France
    Rev Med Interne 24:730-7. 2003
    ..The lack of compensation is responsible for type 2 diabetes. When permanent hyperglycemia is present, progressive insulin secretory failure with time ensues, due to glucotoxicity and to lipotoxicity...
  7. ncbi request reprint [Type II diabetes in children and adults]
    Pierre Jean Guillausseau
    Service de Medecine B, hôpital Lariboisière et faculté de médecine Lariboisière Saint Louis, Universite Paris 7 Denis Diderot, 75475 Paris
    Rev Prat 53:1463-71. 2003
  8. ncbi request reprint Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice
    P J Guillausseau
    Service de Medecine B, Hopital Lariboisiere, Paris et Université Paris 7 Denis Diderot, France
    Diabetes Metab 29:79-81. 2003
    ..To address compliance with oral antidiabetic agents and its impact on metabolic control in type 2 diabetic patients treated in general practice...
  9. ncbi request reprint 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily
    P J Guillausseau
    Service de Medecine B, Hopital Lariboisiere, 2 rue Ambroise Pare, 75010 Paris, France
    Diabetes Metab 27:133-7. 2001
    ..The present study was undertaken to assess the effect of a new formulation of gliclazide administered once daily, gliclazide modified release, on plasma glucose levels over 24 hours...
  10. ncbi request reprint Ketosis-prone type 2 diabetes in patients of sub-Saharan African origin: clinical pathophysiology and natural history of beta-cell dysfunction and insulin resistance
    Franck Mauvais-Jarvis
    Department of Endocrinology and Diabetes, Saint Louis Hospital and University of Paris VII School of Medicine, Paris, France
    Diabetes 53:645-53. 2004
    ....
  11. ncbi request reprint [Drug treatment of type 2 diabetes]
    Amélie Tielmans
    Service de médecine interne B, AP HP, Hopital Lariboisiere, 75010 Paris, France
    Presse Med 36:269-78. 2007
    ..GLP-1 (Glucagon-Like Peptide-1) analogs and DPP-IV (dipeptidyl-peptidase-IV) inhibitors are new drug classes currently under development...
  12. ncbi request reprint [Drug treatment in type 2 diabetes (part 2)]
    Amélie Tielmans
    Service de médecine interne B, AP HP, Hopital Lariboisiere, Paris
    Presse Med 36:467-74. 2007
    ..5%. New guidelines for management of type 2 diabetes were published in 2006...
  13. doi request reprint Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy
    Amelie Lecleire-Collet
    Departments of Ophthalmology, Hopital Fernand Widal, Assistance Publique Hopitaux de Paris, Paris 7 University, Paris, France
    Invest Ophthalmol Vis Sci 52:2861-7. 2011
    ..To correlate retinal function with vascular response to flicker light in normotensive patients with diabetes without diabetic retinopathy (DR)...
  14. ncbi request reprint A possible hypophosphatemia-induced, life-threatening encephalopathy in diabetic ketoacidosis: a case report
    Bruno Megarbane
    Medical Critical Care Department, Lariboisiere Hospital, Paris, France
    Am J Med Sci 333:384-6. 2007
    ..Our data strongly suggest that phosphate depletion-induced encephalopathy probably originates from direct impairment of cerebral electrophysiological activity rather than from cardiac flow alteration...
  15. doi request reprint Immunocytochemistry with cytokeratin 19 and anti-human mesothelial cell antibody (HBME1) increases the diagnostic accuracy of thyroid fine-needle aspirations: preliminary report of 150 liquid-based fine-needle aspirations with histological control
    Beatrix Cochand-Priollet
    Department of Pathology and Cytopathology, Lariboisiere Hospital, Paris, France
    Thyroid 21:1067-73. 2011
    ..We aimed to assess the diagnostic accuracy of immunocytochemistry (ICC) of thyroid FNA to improve its sensitivity and specificity...
  16. doi request reprint Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials
    Nish Chaturvedi
    International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College Healthcare NHS Trust, London, UK
    Lancet 372:1394-402. 2008
    ..We therefore designed the DIabetic REtinopathy Candesartan Trials (DIRECT) Programme to assess whether candesartan could reduce the incidence and progression of retinopathy in type 1 diabetes...
  17. doi request reprint Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial
    Anne Katrin Sjølie
    Department of Ophthalmology, Odense University Hospital, Odense, Denmark
    Lancet 372:1385-93. 2008
    ..Diabetic retinopathy remains a leading cause of visual loss in people of working age. We examined whether candesartan treatment could slow the progression and, secondly, induce regression of retinopathy in people with type 2 diabetes...
  18. ncbi request reprint PROactive study
    Pierre Jean Guillausseau
    Lancet 367:23; author reply 26-7. 2006